SecBot SecBot

TOVX

Theriva Biologics, Inc.
NYSE· Pharmaceutical Preparations· Inc. NV· CIK 0000894158 Biotech & Drug Discovery
$0.1400 +0.00 (+0.00%)
Nov 16 4:00 PM ET · prev $0.1400
Market cap
$7.3M
Nano cap
Median target
$4.00
+2757% · range $4.00–4.00
1 year
−41.7%
from $0.2400 · Nov 17
30 days
−30.0%
from $0.2000
52-week range
$0.1400–0.4100
−66% from high · low Nov 13
Avg volume 20D
5.30M
Nov 2 spike 91.36M
Short interest
1.41M
≈3.1% of shares · −23.4%
Days to cover
2.7
at average volume
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2026: 1 added (0 new), 2 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.050 → −$0.060 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersCOVERING

    Short interest −23.4% to 1.41M shares. 2.7 days to cover, ≈3.1% of shares.

  • TrendDOWNTREND

    32% below its 50-day average. New closing low $0.1400 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCTRIM161,106$36.2K
RENAISSANCE TECHNOLOGIES LLCADD109,500$24.6K
UBS Group AGNEAR_EXIT13,983$3.1K
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED486,179$121.5K
JANE STREET GROUP, LLCADD331,922$83.0K
GEODE CAPITAL MANAGEMENT, LLCTRIM294,021$73.6K
UBS Group AGTRIM61,053$15.3K
OSAIC HOLDINGS, INC.DOUBLED441$110.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Mar 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +2757%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Mar 31, 2026Maxim Group
UPGRADE
UPGRADEBuy
May 8, 2025Maxim Group
DOWNGRADE
DOWNGRADEHold
Nov 13, 2024Maxim Group
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
−$0.06
EPS estimate, this quarter
−20%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.06-$0.06–-$0.06-20.0%$0.00
Next Q-$0.05-$0.05–-$0.05No data$0.00
Current FY-$0.25-$0.25–-$0.25-25.0%$300.0K
Next FY-$0.20-$0.20–-$0.20+0.0%$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
1,414,042
shares short
-23.4%
vs prior settlement
2.7
days to cover
≈3.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.

SecBot reports

9 filings · 2 press releases · 2 bullish · 2 bearish · 1 mixed · 4 neutral
All TOVX filing & press-release reports (11)